Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2.

Lyons TR, O'Brien J, Borges VF, Conklin MW, Keely PJ, Eliceiri KW, Marusyk A, Tan AC, Schedin P.

Nat Med. 2011 Aug 7;17(9):1109-15. doi: 10.1038/nm.2416.

2.

Non-steroidal anti-inflammatory drugs target the pro-tumorigenic extracellular matrix of the postpartum mammary gland.

O'Brien J, Hansen K, Barkan D, Green J, Schedin P, O'Brien J, Hansen K, Barkan D, Green J, Schedin P.

Int J Dev Biol. 2011;55(7-9):745-55. doi: 10.1387/ijdb.113379jo.

3.

Cyclooxygenase-2-dependent lymphangiogenesis promotes nodal metastasis of postpartum breast cancer.

Lyons TR, Borges VF, Betts CB, Guo Q, Kapoor P, Martinson HA, Jindal S, Schedin P.

J Clin Invest. 2014 Sep;124(9):3901-12. doi: 10.1172/JCI73777. Epub 2014 Aug 18.

4.

Rat mammary extracellular matrix composition and response to ibuprofen treatment during postpartum involution by differential GeLC-MS/MS analysis.

O'Brien JH, Vanderlinden LA, Schedin PJ, Hansen KC.

J Proteome Res. 2012 Oct 5;11(10):4894-905. doi: 10.1021/pr3003744. Epub 2012 Aug 30.

5.

Wound healing-like immune program facilitates postpartum mammary gland involution and tumor progression.

Martinson HA, Jindal S, Durand-Rougely C, Borges VF, Schedin P.

Int J Cancer. 2015 Apr 15;136(8):1803-13. doi: 10.1002/ijc.29181. Epub 2014 Sep 15.

6.

Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species.

O'Brien J, Lyons T, Monks J, Lucia MS, Wilson RS, Hines L, Man YG, Borges V, Schedin P.

Am J Pathol. 2010 Mar;176(3):1241-55. doi: 10.2353/ajpath.2010.090735. Epub 2010 Jan 28.

7.

Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis.

McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W, Schedin P.

Am J Pathol. 2006 Feb;168(2):608-20.

8.

Postpartum breast involution reveals regression of secretory lobules mediated by tissue-remodeling.

Jindal S, Gao D, Bell P, Albrektsen G, Edgerton SM, Ambrosone CB, Thor AD, Borges VF, Schedin P.

Breast Cancer Res. 2014 Mar 28;16(2):R31. doi: 10.1186/bcr3633.

9.

Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model.

Tran-Thanh D, Buttars S, Wen Y, Wilson C, Done SJ.

Cancer Prev Res (Phila). 2010 Feb;3(2):202-11. doi: 10.1158/1940-6207.CAPR-09-0181. Epub 2010 Jan 26.

10.

Mammary gland involution as an immunotherapeutic target for postpartum breast cancer.

Fornetti J, Martinson HA, Betts CB, Lyons TR, Jindal S, Guo Q, Coussens LM, Borges VF, Schedin P.

J Mammary Gland Biol Neoplasia. 2014 Jul;19(2):213-28. doi: 10.1007/s10911-014-9322-z. Epub 2014 Jun 22. Review.

11.

Role of COX-2 in epithelial-stromal cell interactions and progression of ductal carcinoma in situ of the breast.

Hu M, Peluffo G, Chen H, Gelman R, Schnitt S, Polyak K.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3372-7. doi: 10.1073/pnas.0813306106. Epub 2009 Feb 13.

12.

Annexin A8 is up-regulated during mouse mammary gland involution and predicts poor survival in breast cancer.

Stein T, Price KN, Morris JS, Heath VJ, Ferrier RK, Bell AK, Pringle MA, Villadsen R, Petersen OW, Sauter G, Bryson G, Mallon EA, Gusterson BA.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6872-9.

13.

Macrophages are crucial for epithelial cell death and adipocyte repopulation during mammary gland involution.

O'Brien J, Martinson H, Durand-Rougely C, Schedin P.

Development. 2012 Jan;139(2):269-75. doi: 10.1242/dev.071696. Epub 2011 Nov 30.

14.

Pregnancy-associated breast cancers are driven by differences in adipose stromal cells present during lactation.

McCready J, Arendt LM, Glover E, Iyer V, Briendel JL, Lyle SR, Naber SP, Jay DG, Kuperwasser C.

Breast Cancer Res. 2014 Jan 9;16(1):R2. doi: 10.1186/bcr3594.

15.

Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.

Lofgren KA, Ostrander JH, Housa D, Hubbard GK, Locatelli A, Bliss RL, Schwertfeger KL, Lange CA.

Breast Cancer Res. 2011 Sep 17;13(5):R89. doi: 10.1186/bcr2946.

16.

Cyclooxygenase-2 directly induces MCF-7 breast tumor cells to develop into exponentially growing, highly angiogenic and regionally invasive human ductal carcinoma xenografts.

Robertson FM, Mallery SR, Bergdall-Costell VK, Cheng M, Pei P, Prosperi JR, Ferrari M.

Anticancer Res. 2007 Mar-Apr;27(2):719-27.

17.

The role of COX-2 inhibition in breast cancer treatment and prevention.

Arun B, Goss P.

Semin Oncol. 2004 Apr;31(2 Suppl 7):22-9. Review.

PMID:
15179621
18.

Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer.

Barnes NL, Warnberg F, Farnie G, White D, Jiang W, Anderson E, Bundred NJ.

Br J Cancer. 2007 Feb 26;96(4):575-82. Epub 2007 Feb 6.

19.

Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution.

Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, Morrison MM, Lim J, Williams M, Brantley-Sieders DM, Balko JM, Tonetti D, Earp HS 3rd, Cook RS.

J Clin Invest. 2014 Nov;124(11):4737-52. doi: 10.1172/JCI76375. Epub 2014 Sep 24.

20.

Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma.

Tuynman JB, Buskens CJ, Kemper K, ten Kate FJ, Offerhaus GJ, Richel DJ, van Lanschot JJ.

Ann Surg. 2005 Dec;242(6):840-9, discussion 849-50.

Items per page

Supplemental Content

Write to the Help Desk